As­traZeneca, Dai­ichi Sankyo’s En­her­tu im­press­es in 'game-chang­ing' study with many can­cers: #AS­CO23

CHICA­GO — As­traZeneca and Dai­ichi Sankyo’s En­her­tu showed promis­ing ef­fi­ca­cy in a range of can­cers — par­tic­u­lar­ly gy­ne­co­log­ic can­cers — that ex­press the bio­mark­er HER2, ac­cord­ing to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER